## Hemoptysis in COVID-19 Patients: Fire under the Ashes?

ArashEatemadi <sup>1</sup>,Fatemeh Mir Nezhad <sup>2</sup>, Thuwaiba Al Baluki <sup>1</sup>, Fatma Al Kamashki <sup>3</sup>, ImanMohammadi <sup>4</sup> <sup>1</sup> Department of General Medicine, Suhar hospital, Suahr, Sultanate of Oman <sup>2</sup>Seeb polyclinic, Seeb, Muscat governorate, Ministry of health, Sultanate of Oman <sup>3</sup> General foundation program, Oman medical speciality board, Suhar hospital, Suhar, Sultanate of Oman <sup>4</sup> Center for emergency management, Ministry of Health, Muscat, Sultanate of Oman

Abstract:- Hemoptysis is a terrifying symptom for patients complicated with all types of pneumonia, regardless of etiology. A minor proportion of COVID-19 patients have suffered fromhemoptysis. Among COVID-19 patients, this symptom might be detected during admission in severe cases or even as a presenting sign to the emergency. In any scenario, clinicians should think to causes of hemoptysis in these patients, whilst pulmonary emboli definitely on top.

## Keywords: COVID-19, Hemoptysis, Pulmonary Emboli.

Physicians treat COVID-19 patients sometimes are facing non- classic clinical picture of Cough, fever and shortness of breath. Recently became evident that COVID-19 is an inflammatory, thrombogenic disease and especially severe patients often have high d-dimers, fibrinogen and fibrin degradation products (FDP). (1)

Hemoptysiscould be seen in various diseases such as tuberculosis, malignancy, bronchiectasis, pulmonary hemorrhage, pulmonary embolism, vasculitis, coagulation disorders and severe pneumonia. (2). However, Hemoptysis is a rare symptom of COVID-19.(3-6). Hemoptysis sometimes massive –could be the first presentation of SARS-CoV-2 infection. (7,8)

There are increasing evidences about thromboembolic complications of COVID-19 (9,10) Hemoptysis in COVID-19 patients might be due to pulmonary emboli (PE) or not; however, the former is more common.COVID-19 patients with pulmonary embolism reportedly present with hypoxemia, chest pain, dyspnea, hemoptysis, and elevated D-dimer. (11) Generally, hemoptysis is a rare presentation of COVID-19, however, it is more common in patients complicated with PE (reaching up to 13%). (12,13) patients in the Prospective Investigation of Pulmonary Embolism (PIOPED) group were noted to have hemoptysis in 13% of PE cases. (14) Hemoptysis was also one of the clinical features with the highest association with PE in the final logistic regression model of the Pulmonary Embolism Rule Out Criteria (PERC). (15)

The correlation between COVID-19 and PE makes a diagnostic dilemma for clinicians. High D-Dimer levels (>1.0 mg/dl), although has been suggested as a marker of increased COVID-19 severity, but is not specific to PE

diagnosis. (16,17) Therefore, reliance on D-dimer as PE diagnosis marker should be interpreted cautiouslyin COVID-19. The suspected cases, should underwent Computed Tomography Angiography (CTA) to establish PE diagnosis whilst the risk of acute kidney injury due to intravenous contrast media should be considered. In addition to CTA, bedside tests such as ECG or echocardiography might be helpful to recognize COVID-19 patients complicated with PE.

Apart from PE, other causes of hemoptysis should be rigorously investigated, including Heparin overdose or warfarin toxicity (used for treatment of PE), Superimposed aspergillosis(18) and pulmonary hemorrhage (19)

In conclusion, COVID-19 patients occasionally come with atypical presentations or usual symptoms with different underlying pathologies warrant different diagnostic and therapeutic approach. During COVID-19 crisis, in any given patient presented with hemoptysis, clinician should think about COVID-19 and after confirmation, then pulmonary emboli should be rigorously ruled out.

## REFERENCES

- Han H., Yang L., Liu R., Liu F., Wu K.L. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med (CCLM) Mar 2020 doi: 10.1515/cclm-2020-0188.
- [2]. Mondoni M, Carlucci P, Job S, Parazzini EM, Cipolla G, Pagani M, et al. Observational, multicentre study on the epidemiology of haemoptysis. Eur Respir J. 2018. https://doi.org/10.1183/13993003.01813-2017.
- [3]. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395:507-13. Back to cited text no. 4
- [4]. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497– 506.
- [5]. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708–20.

ISSN No:-2456-2165

- [6]. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606.
- [7]. Elise Peys, Dieter Stevens, Yannick VandeWeygaerde, Thomas Malfait, Laurens Hermie, Philippe Rogiers, Pieter Depuydt, Eva Van Braeckel. Haemoptysis as the first presentation of COVID-19: a case report. BMC Pulmonary Medicine (2020) 20:275. https://doi.org/10.1186/s12890-020-01312-6
- [8]. SerapArgunBarış,İlkimSemaCoşkun, GözdeSelvi, HaşimBoyacı, İlknurBaşyiğit. Case Series of COVID-19 Presenting with Massive Hemoptysis. Turk Thorac J. 2020 Nov; 21(6): 454–456. Published online 2020 Nov 1. doi: 10.5152/TurkThoracJ.2020.20150)
- [9]. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J ThrombHaemost. 2020 Apr 09; doi: 10.1111/jth.14830.
- [10]. Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur. Heart J. 2020 Mar 30
- [11]. Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography. Thromb Res. 2020; 190:58–59.
- [12]. Casey K, Iteen A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020; 38: 1544.e1– 1544.e3. doi: 10.1016/j.ajem.2020.04.011.
- [13]. Shi F, Yu Q, Huang W, Tan C. 2019 Novel Coronavirus (COVID-19) Pneumonia with hemoptysis as the initial symptom: CT and clinical features. Korean J Radiol. 2020; 21:537–40. doi: 10.3348/kjr.2020.0181.
- [14]. Stein P.D., Terrin M.L., Hales C.A., Palevsky H.I., Saltzman H.A. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest. 1991;100(3):598.
- [15]. Kline J.A., Mitchell A.M., Kabrhel C., Richman P.B., Courtney D.M. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J. Thromb. Haemost. 2004 Aug;2(8):1247–1255.
- [16]. Wang D., Hu B., Hu C., Zhu F., Liu X. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7 doi: 10.1001/jama.2020.1585.
- [17]. Zhou F., Yu T., Du R., Fan G., Liu Y. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062.

- [18]. Ravi Karan Patti, Nishil R. Dalsania, Navjot Somal, Ankur Sinha, Sanwal Mehta, Monica Ghitan, Chanaka Seneviratne, Yizhak Kupfer. Subacute Aspergillosis "Fungal Balls" Complicating COVID-19. J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8: 2324709620966475. Published online 2020 Oct 15. doi: 10.1177/2324709620966475
- [19]. Christian Löffler, Juliane Mahrhold, Peter Fogarassy, Martin Beyer, Bernhard Hellmich. Two Immunocompromised Patients with Diffuse Alveolar Hemorrhage as a Complication of Severe Coronavirus Disease 2019. Chest. 2020 Nov; 158(5): e215-e219. Published online 2020 Inl 2. doi: 10.1016/j.chest.2020.06.051